FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380080902> ?p ?o ?g. }

• W4380080902 endingPage "1683" @default.
• W4380080902 startingPage "1683" @default.
• W4380080902 abstract "Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been suggested to have anti-inflammatory properties in diabetes. The goal of this study was to evaluate the role of the SGLT2 inhibitor dapagliflozin (DAPA) in the attenuation of lipopolysaccharide (LPS)-induced hypotension. Male Wistar albino rats were divided into normal and diabetic groups and received DAPA (1 mg/kg/day) for two weeks followed by a single dose of 10 mg/kg LPS. Blood pressure was recorded throughout the study and the circulatory levels of cytokines were assessed using a multiplex array, while the aortas were harvested for analysis. DAPA attenuated the vasodilation and hypotension caused by LPS. Mean arterial pressure (MAP) was preserved in the normal and diabetic DAPA-treated septic groups (MAP = 83.17 ± 5.27, 98.43 ± 5.57 mmHg) compared to the vehicle-treated septic groups (MAP = 65.60 ± 3.31, 68.21 ± 5.88 mmHg). Most of the cytokines induced by LPS were decreased in the DAPA-treated septic groups. In the aorta, the inducible nitric oxide synthase-derived nitric oxide had lower expression in the DAPA-treated rats. In contrast, the expression of α-smooth muscle actin, a marker of the vessel's contractile state, was higher in the DAPA-treated rats in comparison with non-treated septic rats. These findings revealed that the protective role of DAPA against LPS-induced hypotension is likely to be glucose-lowering independent, as was observed in the non-diabetic septic group. Taken together, the results show that DAPA has a potential effect in the prevention of the hemodynamic disturbances of sepsis regardless of glycemia levels." @default.
• W4380080902 created "2023-06-10" @default.
• W4380080902 creator A5029067776 @default.
• W4380080902 creator A5051685038 @default.
• W4380080902 creator A5052244635 @default.
• W4380080902 creator A5054260049 @default.
• W4380080902 creator A5062258172 @default.
• W4380080902 date "2023-06-08" @default.
• W4380080902 modified "2023-09-28" @default.
• W4380080902 title "Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level" @default.
• W4380080902 cites W1189167250 @default.
• W4380080902 cites W1999325378 @default.
• W4380080902 cites W2023244494 @default.
• W4380080902 cites W2068834516 @default.
• W4380080902 cites W2077208103 @default.
• W4380080902 cites W2079179318 @default.
• W4380080902 cites W2101590720 @default.
• W4380080902 cites W2116140667 @default.
• W4380080902 cites W2551481457 @default.
• W4380080902 cites W2618159646 @default.
• W4380080902 cites W2705431294 @default.
• W4380080902 cites W2765666929 @default.
• W4380080902 cites W2883565374 @default.
• W4380080902 cites W2898328058 @default.
• W4380080902 cites W2902679839 @default.
• W4380080902 cites W2908889353 @default.
• W4380080902 cites W2922803436 @default.
• W4380080902 cites W2958636619 @default.
• W4380080902 cites W2966711556 @default.
• W4380080902 cites W2970624317 @default.
• W4380080902 cites W3000302862 @default.
• W4380080902 cites W3011885872 @default.
• W4380080902 cites W3022230909 @default.
• W4380080902 cites W3023197304 @default.
• W4380080902 cites W3067520652 @default.
• W4380080902 cites W3081830235 @default.
• W4380080902 cites W3088173406 @default.
• W4380080902 cites W3102435759 @default.
• W4380080902 cites W3118825091 @default.
• W4380080902 cites W3137735028 @default.
• W4380080902 cites W3155121970 @default.
• W4380080902 cites W3155806036 @default.
• W4380080902 cites W3161647020 @default.
• W4380080902 cites W3162621824 @default.
• W4380080902 cites W3164030736 @default.
• W4380080902 cites W3193297191 @default.
• W4380080902 cites W3216568701 @default.
• W4380080902 cites W4200015918 @default.
• W4380080902 cites W4206443449 @default.
• W4380080902 cites W4210844311 @default.
• W4380080902 cites W4224984600 @default.
• W4380080902 cites W4226287097 @default.
• W4380080902 cites W4283161412 @default.
• W4380080902 cites W4293354639 @default.
• W4380080902 cites W4295420683 @default.
• W4380080902 cites W4308183941 @default.
• W4380080902 cites W4309739357 @default.
• W4380080902 cites W4320920648 @default.
• W4380080902 cites W4365135539 @default.
• W4380080902 doi "https://doi.org/10.3390/pharmaceutics15061683" @default.
• W4380080902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37376131" @default.
• W4380080902 hasPublicationYear "2023" @default.
• W4380080902 type Work @default.
• W4380080902 citedByCount "0" @default.
• W4380080902 crossrefType "journal-article" @default.
• W4380080902 hasAuthorship W4380080902A5029067776 @default.
• W4380080902 hasAuthorship W4380080902A5051685038 @default.
• W4380080902 hasAuthorship W4380080902A5052244635 @default.
• W4380080902 hasAuthorship W4380080902A5054260049 @default.
• W4380080902 hasAuthorship W4380080902A5062258172 @default.
• W4380080902 hasBestOaLocation W43800809021 @default.
• W4380080902 hasConcept C120770815 @default.
• W4380080902 hasConcept C126322002 @default.
• W4380080902 hasConcept C134018914 @default.
• W4380080902 hasConcept C170493617 @default.
• W4380080902 hasConcept C2776452961 @default.
• W4380080902 hasConcept C2776914184 @default.
• W4380080902 hasConcept C2777180221 @default.
• W4380080902 hasConcept C2777422806 @default.
• W4380080902 hasConcept C2777622882 @default.
• W4380080902 hasConcept C2777953023 @default.
• W4380080902 hasConcept C2778754761 @default.
• W4380080902 hasConcept C2779395532 @default.
• W4380080902 hasConcept C2779935178 @default.
• W4380080902 hasConcept C2992686903 @default.
• W4380080902 hasConcept C519581460 @default.
• W4380080902 hasConcept C555293320 @default.
• W4380080902 hasConcept C71924100 @default.
• W4380080902 hasConcept C84393581 @default.
• W4380080902 hasConcept C98274493 @default.
• W4380080902 hasConceptScore W4380080902C120770815 @default.
• W4380080902 hasConceptScore W4380080902C126322002 @default.
• W4380080902 hasConceptScore W4380080902C134018914 @default.
• W4380080902 hasConceptScore W4380080902C170493617 @default.
• W4380080902 hasConceptScore W4380080902C2776452961 @default.
• W4380080902 hasConceptScore W4380080902C2776914184 @default.
• W4380080902 hasConceptScore W4380080902C2777180221 @default.
• W4380080902 hasConceptScore W4380080902C2777422806 @default.

• next